Key result
Long-term N-acetylprocainamide reduces PVC frequency and normalizes PEP/LVET versus placebo.
Why the study?
Does long-term N-acetylprocainamide therapy improve PVC frequency and left ventricular function in patients with chronic PVCs?
Does long-term N-acetylprocainamide therapy improve PVC frequency and left ventricular function in patients with chronic PVCs?
Long-term N-acetylprocainamide therapy appears well tolerated with a low rate of abnormal ANA titers, and may improve underlying PVC frequency and left ventricular function over one year.
Answers are grounded in this paper and cite their sources.
May support N-acetylprocainamide evaluation in chronic PVCs; leaves open confirmation in prospective trials.
The effects of long-term NAPA therapy were evaluated in 6 patients with chronic PVCs known to respond to this drug during a previous placebo-controlled, dose-ranging trial. Underlying cardiac status was evaluated every six months by switching each patient from NAPA to placebo. Placebo period PVC frequency after one year of NAPA therapy was reduced, compared to baseline placebo values. Mean PEP/LVET, measured while the patients received placebo, was elevated at the beginning of the study but was normal after one year of NAPA therapy. Comparison of NAPA and placebo period observations indicated a reduction in PEP/LVET when NAPA therapy was begun. This effect, however, could not be demonstrated one year later when mean placebo period PEP/LVET was normal. The apparent dependence of this effect on underlying status of left ventricular function suggests that the initial reduction in PEP/LVET represents an an indirect effect of NAPA rather than a direct inotropic action. NAPA therapy was well tolerated by the 6 patients and ANA titers became abnormal in only one, in marked contrast to reported experience with procainamide.
No takes yet. Share an insight, caveat, or question.
Lertora et al. (1979) studied chronic PVCs (n=6). N-acetylprocainamide (NAPA) vs. placebo was evaluated on PVC frequency and PEP/LVET. Long-term N-acetylprocainamide therapy in 6 patients with chronic PVCs reduced placebo-period PVC frequency and normalized PEP/LVET after one year, with abnormal ANA titers in only 1 patient.
Synapse has enriched 10 related papers. Consider them for comparative context: